Gilles Laverny

16PUBLICATIONS
57CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Physical organic chemistryGlycoconjugates
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Apr 09, 2026
Impaired vitamin D signaling reveals neutrophils as key drivers of prostate cancer dissemination.

Kateryna Len-Tayon, Justine Gantzer, Charles Dariane

|Mar 28, 2026
HIF1 inhibition targets tumoral and myeloid cells, and is a promising therapy for metastatic castration-resistant prostate cancer.

Darya Yanushko, Angélique Pichot, Alexandre Vincent

|Feb 02, 2026
Targeting pre-existing club-like cells in prostate cancer potentiates androgen deprivation therapy.

Manon Baurès, Anne-Sophie Vieira Aleixo, Emeline Pacreau

|Sep 26, 2025
Characterization of the immune landscape in healthy mouse prostate and during prostate cancer progression.

Despoina Pervizou, Joanna De Chiara, Lionel Spinelli

|Mar 03, 2025
[New insights of vitamin D-based therapy for prostate cancer].

Kateryna Len-Tayon, Daniel Metzger, Gilles Laverny

|Jan 26, 2025
p53-loss induced prostatic epithelial cell plasticity and invasion is driven by a crosstalk with the tumor microenvironment.

Darya Yanushko, Beatriz German Falcon, Rana El Bizri

Pageof 3

Frequent Collaborators

12 joint publications

Daniel Metzger

5 joint publications

Daniela Rovito

4 joint publications

Kateryna Len-Tayon

4 joint publications

Darya Yanushko